The avian adeno-associated virus (AAAV) has been proved to be an efficient gene transfer vector for human gene therapy and vaccine research. In this experiment, an AAAV-based vaccine was evaluated for the development of a vaccine against duck hepatitis a virus type 1 (DHAV-1). The major capsid VP1 gene was amplified and subcloned into pFBGFP containing the inverted terminal repeats of AAAV, and then the recombinant baculovirus rBac-VP1 was generated. The recombinant AAAV expressing the VP1 protein (rAAAV-VP1) was produced by co-infecting Sf9 cells with rBac-VP1 and the other 2 baculoviruses containing AAAV functional genes and structural genes respectively, and confirmed by electron microscopy, Western blotting and immunofluorescence assays. Quantitative real-time PCR revealed that the titer of rAAAV-VP1 was about 9 × 10 12 VG/mL. Immunogenicity was studied in ducklings. One day ducklings were injected intramuscularly once with rAAAV-VP1. Serum from rAAAV-VP1-vaccinated ducklings showed a systemic immune response evidenced by VP1-specific enzymelinked immunosorbent assay and virus neutralization test. Furthermore, all ducklings inoculated with rAAAV-VP1 were protected against DHAV-1 challenge. The data of quantitative real-time RT-PCR from livers of challenged ducklings also showed that the level of virus copies in rAAAV-VP1 group was significantly lower than that of the PBS group. Collectively, these results demonstrate that the AAAV-based vaccine is a potential vaccine candidate for the control of duck viral hepatitis.
INTRODUCTION
Duck hepatitis a virus (DHAV) is the etiological agent of duck viral hepatitis, it can cause a highly contagious and rapidly spreading viral infection in young ducklings associated with liver necrosis and high mortality up to 100% (Levine and Fabricant, 1950) . The DHAV is genetically divided into 3 serotypes: the worldwide traditional serotype DHAV-1, a serotype recently isolated in Taiwan DHAV-2, and a serotype isolated in South Korea and China DHAV-3 (Kim et al., 2007; Kim et al., 2008; Liu et al., 2011) , and there is no cross-neutralization among them .
The DHAV belongs to the new genus Avihepatovirus of the family picornaviridae. The full sequences of DHAV genome have been reported (Kim et al., 2006; Ding and Zhang, 2007) frame encodes a polyprotein of 2249 amino acids, which is hydrolyzed into 12 mature polypeptides by its own protease. Among the 3 structural proteins VP0, VP1, and VP3, the VP1 protein is the major host-protective antigen of DHAV, it contains potential T and B cell epitopes that induce protective neutralizing antibodies (Wu et al., 2015; Zhang et al., 2015) . In addition, VP1 may be relevant in DHAV evolution, pathogenicity and virulence (Jin et al., 2008; Liu et al., 2008; Wang et al., 2008a) .
Control of DHAV is currently attempted using attenuated vaccine. Immunization of duckling against DHAV, with expression system expressing the VP1, has been previously reported and includes the use of Pichia pastoris , a suicidal DNA plasmid (Fu et al., 2012) , and adenovirus (Yin et al., 2013) . The advantages of the genetic engineering vaccines include no reversion to pathogenicity of vaccine virus and that the vaccine can be tailor-made to match field virus phenotype. Therefore, the development of a safe and efficient new genetic engineering vaccine to control the disease is a promising direction in the future.
The adeno-associated virus is a small nonpathogenic parvovirus that has been widely used in gene therapy and gene engineering vaccine research (Wright et al., 112 2003) . The avian adeno-associated (AAAV) virus has also been proved to be an efficient vector for gene delivery. It was reported that AAAV could mediate the VP2 gene expression of infectious bursal disease virus and provide enough protection against virus challenge (Perozo et al., 2008a) . In our previous studies, AAAV has successfully mediated the long-lasting expression of the GFP reporter gene and other genes in AAAV infected avian cells and ducklings (Wang et al., 2007; Wang et al., 2008b; Wang et al., 2009) . The aim of this work was to construct recombinant AAAV (rAAAV) expressing the major structural protein VP1 of DHAV-1 and evaluate the protection against DHAV-1 challenge in ducklings vaccinated with rAAAV.
MATERIALS AND METHODS

Cells and Virus
Spodoptera frugiperda Sf9 cells (Invitrogen, Carlsbad, CA) were cultured at 27
• C in Sf-900 II serum-free medium (Gibco BRL, Grand Island, NY). Chicken embryonic fibroblast DF1 cells 203) were maintained in Dulbecco's modified Eagle's medium (DMEM, Gibco) supplemented with 10% fetal calf serum. DHAV-1 strain SH (Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, China) was propagated in duck embryos as described previously (Song et al., 2014) , the virus was stored at −80
• C until use. The recombinant baculovirus rBac-VP and rBac-Rep expressing the Cap and Rep proteins of AAAV, respectively, were generated as described (Wang et al., 2017a ) and stored at 4
• C until use.
Construction of Recombinant Baculovirus
The DHAV-1 VP1 gene between nucleotides 2066 and 2779 (GenBank accession no. FJ157178) was amplified by PCR from pFB-P13CD vector (Wang et al., 2018) using primers 5 -gtactcgagaccATGGGTGATTCCAAC CAGTTGGGG-3 and 5 -cgagcggccgcTTATTC AATTTCCAGATTGAGTTC-3 (Xho I and Not I sites are underlined; uppercases indicate the VP1 coding sequence). A start codon (ATG) and a stop codon (TAA) were included in the primers, and a Kozak sequence was introduced in front of the start codon to increase the VP1 protein translation. The amplified VP1 gene was cut with Xho I and Not I, cloned downstream of the CMV promoter in a previously developed vector called pFBAGFP containing the inverted terminal repeats of AAAV (Wang et al., 2017a) . The recombinant plasmid was named pFB-VP1 (Figure 1 ). The recombinant vector pFB-VP1 was used to produce recombinant baculoviruses rBac-VP1 by following the manufacturer's instruction of Bac-to-Bac Baculovirus Expression System (Invitrogen). 
Production and Purification of rAAAV-VP1 Particles
To produce the rAAAV in insect cells, Sf9 cells at a density of 2 × 10 6 cells/mL in 200 mL suspension culture were infected with rBacVP, rBacRep, and rBac-VP1 (MOI 5 each). About 72 h later, the cells were collected by centrifugation, lysed by repeated freezing, and thawing from −80
• C to 37
• C 3 times. The rAAAV vector, namely rAAAV-VP1, was purified by using the PEG precipitation method as described previously (Matsushita et al., 1998) . Briefly, the supernatants of the cell lysates were extracted in 1/10 volume of chloroform by vigorous shaking at room temperature for 1 h. The viral particles in the upper phase were precipitated with 10% (wt/vol) PEG8000, and the precipitation was re-suspended in PBS, aliquoted, and stored at −80
• C.
Identification of rAAAV-VP1 Particles
To identify rAAAV-VP1 morphologically, the purified viral particles were identified by electron microscopy (EM). The samples were mounted on a carbon-coated paper grid for 10 min, drained with a filter paper. After being negatively strained with 2% phosphotumgstic acid (pH7.4) for 1 min, the samples were observed under a transmission electron microscope (TEM; Tecnai 12, FEI, Hillsboro, Oregon). To identify rAAAV-VP1 immunologically, the purified viral particles were run on 8% SDS-PAGE and the proteins were transferred onto polyvinylidene difluoride membrane (F. Hoffmann-La Roche Ltd., Grenzacherstrasse, Switzerland). The membranes were blocked overnight with 10% skimmed milk in PBS, and incubated for 2 h at room temperature with mouse anti-VP3 antibody (1:100), which was produced by immunizing mice 3 times with 50 μg of E. coli-expressed AAAV Cap protein as described previously (Li et al., 2013) . After washing 3 times in PBST, the membranes were incubated for 1 h with horseradish peroxidase-labeled goat anti-mouse IgG (1:2000; Jackson ImmunoResearch, USA). The protein bands were visualized by 3, 3 -diaminobenzidine tetrahydrochloride staining.
Quantification of rAAAV-VP1 Particles
The concentration of vector genomes (VG) was determined by real-time PCR on an iCycler iQ RT-PCR thermocycler (Bio-Rad, Hercules, CA). Proteinase K-treated rAAAV-VP1 was amplified by PCR using SYBR Green master mix (Applied Biosystems, Foster City, CA) with primers specific to the CMV promoter: 5 -ATTTGCGTCAATGGGGCGGAGTT-3 and 5 -CATCAATGGGCGTGGATAGCGGT-3. The cycling conditions were as follows: 95
• C for 3 min, followed by 40 cycles of 95
• C for 15 s, 58
• C for 60 s. Linearized pFB-VP1 was used as a copy number standard to make a standard curve.
Detection of VP1 Expression by Immunofluorescence
DF1 cells were seeded on 24-well plates at a density of 2 × 10 5 cells/well and infected with rAAAV-VP1. Three days after infection, the cells were fixed for 20 min at room temperature with 4% paraformaldehyde and blocked for 60 min with 5%BSA in PBS. Conventional indirect immunofluorescence was performed using mouse anti-VP1 antibody (1:200) as the first antibody, and FITC-labeled goat anti-mouse IgG (1:500; Jackson ImmunoResearch) as the secondary antibody. The mouse anti-VP1 antibody was prepared by using the same method as that of the mouse anti-VP3 method mentioned above.
Detection of VP1 Expression by Western Blotting
DF1 cells were infected with rAAAV-VP1 as described. The cell extract was analyzed by western blotting using mouse anti-VP1 antibody (1:100) as described.
Immunization of Ducklings and Virus Challenge
The animal experiments were performed in accordance with the animal study protocol of the Institutional Animal Care and Use Committee guidelines set by Jiangsu Agri-animal Husbandry Vocational College. One day ducklings were collected from the National Waterfowl Germplasm Resource Pool of Jiangsu Scitech Demonstration Garden of Modern Animal Husbandry, China. The ducklings were randomly divided in 3 groups of 10 and housed separately. The first group was immunized 1 time with rAAAV-VP1 intramuscularly (i.m.) at a dose of 10 9 VG in a volume of 0.5 mL. The second group was immunized i.m. with 10 4.3 ELD 50/ 0.5 mL commercial attenuated vaccine (A66 vaccine, Nanjing Tianbang Co., Nanjing, China). The third group was injected with PBS that served as negative control. Their blood samples were obtained from their leg veins weekly post-immunization. Two weeks after the immunization, half of the inoculated ducklings were challenged i.m. with 0.2 mL of allantoic fluid containing 10 3 LD50 of DHAV-1 strain SH. Three days post-challenge, the ducklings were euthanized by intravenous injection of a 26% solution of sodium pentobarbital, the livers were collected and stored at −80
Enzyme Linked Immunosorbent Assay
Serum samples were measured by using indirect ELISA test using the E. coli-expressed VP1 protein as capture antigen. The VP1 protein was expressed in E. coli BL21 (DE3) using the prokaryotic expression vector pET-30a, and the recombinant proteins were purified by Ni 2+ affinity chromatography His-Bind Resin (Novagen, Madison, WI, USA). The 96-well plates were coated with VP1 protein and incubated overnight at 37
• C. Following blocking with 5% BSA, the plates were incubated with duplicate twofold serial dilutions of test sera for 2 h at 37
• C. After washing with PBST, a horseradish peroxidase-labeled goat anti-duck IgG (KPL, Gaithersburg, MD, USA) was added to each well and incubated for 1 h at 37
• C. The reaction was detected with TMB (3, 3 , 5, 5 -tetramethylbenzidine), and the absorbance was determined at 450 nm using a Bio-Rad microtiter plate reader.
Virus Neutralization Assay
Two-fold serially diluted sera were heat-inactivated at 56
• C for 30 min and incubated with 200 ELD 50 of DHAV-1 strain SH at 37
• C for 1 h. After that, each chicken embryo of 9 d was inoculated with 0.2 mL suspension, and the negative control was injected with 0.2 mL virus suspension containing 200 ELD 50 of DHAV-1 SH strain. According to the mortality, serum neutralization titers were calculated as −log10 of the reciprocal of the highest dilution giving at least 50% neutralization.
Real Time PCR
Total RNA was extracted from 50 mg each of the livers using MinBEST Universal RNA Extraction Kit (TaKaRa, Japan) following the manufacturer's instructions. Extracted RNA was reverse-transcribed using oligo(dT)18 primers (TaKaRa) and M-MLV reverse transcriptase (TaKaRa) following the manufacturer's instructions. A real-time RT-PCR was carried out using primers specific to the 3D gene of DHAV-1: 5 -AAATCAAGGAAGGGAAAACAAGAGGCA-3 and 5 -AACAGCACAACCAGATATAATGAAAGA-3. The cycling conditions were as follows: 95
• C for 15 s, 54
• C for 60 s. Linearized standard plasmid was used to establish a standard curve. A regression curve was constructed plotting the threshold cycle (Ct) values versus the logarithm of the copy number.
Statistical Analysis
Data are expressed as mean ± SD. The difference among groups was analyzed by Student's t-test using SPSS version 13 software. P-values of < 0.05 were considered statistically significant.
RESULTS
Generation and Identification of rAAAV-VP1
To generate the recombinant virus rAAAV-VP1, Sf9 cells were co-infected with rBacVP, rBacRep, and rBac-VP1. After purification with PEG8000 precipitation, the viral particles were subjected to negative staining EM. The typical shape of icosahedral particles with a diameter of approximately 22 nm was observed (Figure 2 ). Western blotting analysis indicated that the viral particles were composed of 3 structural proteins, which were in agreement with the expected (Figure 3) . Quantitative real-time PCR assay showed that the purified rAAAV-VP1 had a titer of 9 × 10 12 VG/mL.
In Vitro VP1 Expression from rAAAV-VP1
To identify the VP1 expression in avian cells mediated by recombinant virus, DF1 cells were infected with rAAAV-VP1. Immunofluorescence assays showed that the recombinant proteins could be recognized by the anti-VP1 antibodies in DF1 cells, whereas no positive signal was observed in negative control cells (Figure 4) . Further western blotting results indicated that the size of the recombinant proteins was about 27 kDa, which was the same as the theoretical value ( Figure 5 ). One day ducklings were vaccinated once with rAAAV-VP1 i.m. at a dose of 10 9 VG or commercial attenuated vaccine. Sera collected at weeks 1, 2, 3, and 4 were analyzed for VP1-specific antibody by ELISA with the E. coli-expressed VP1 protein as capture antigen. The antisera were diluted 1:64 and used in ELISA. The results were obtained from mean ELISA absorbance values of triplicate wells.
rAAAV-VP1 Induces Humoral Immune Responses in Ducklings
The antibodies in the blood samples were measured by an indirect ELISA assay using the E. coli-expressed VP1 protein as the coating antigen. As shown in Figure 6 , the antibodies of both the rAAAV-VP1 vaccinated group and the attenuated vaccine inoculated group were detected at the first week after immunization, reached the maximum at the second week, and then progressively declined at the third week. The mean antibody level of the rAAAV-VP1 vaccinated group was significantly higher (0.01< P < 0.05) than that of the PBS control group. Serum samples were tested further by virus neutralization assay. All ducklings immunized with rAAAV-VP1 and commercial attenuated vaccine produced neutralizing antibodies at 1 wk (ppi). However, all ducklings from the PBS control groups did not develop the detectable neutralizing antibodies during the experiment (Table 1) .
rAAAV-VP1 Provides Protection in Ducklings
To explore whether the recombinant virus rAAAV-VP1 could provide protection in ducklings, each of 3 groups was challenged with wild DHAV-I stain SH on 14 d after the immunization. All the ducklings injected with PBS showed typical clinical signs including watery diarrhea and opisthotonos, ducklings innoculated with the rAAAV-VP1 or attenuated vaccine showed no typical clinical signs (data not shown). To detect viremia of ducklings after DHAV-1 challenge, the livers of the challenged ducklings were collected for real-time RT-PCR analysis using the 3D specific primer. Differences in viral RNA levels were found between livers of vaccinated groups versus those of the PBS group (Figure 7) . Ducklings of the PBS control group had significantly higher virus copy numbers than the rAAAV-VP1 and the attenuated vaccine inoculated groups.
DISCUSSION
Duck viral hepatitis is an acute and highly lethal disease of ducklings, the more common and internationally widespread of the DHAV types is DHAV-1. Currently, prevention of duck viral hepatitis mainly depends on the immunization of ducklings with commercial attenuated vaccines (Kim et al., 2009) . However, there is a potential risk of virulence reversion. Genetic engineering vaccine based on live viral vectors have been proved to be an effective tools for control of avian diseases, such as avian herpesvirus (Tsukamoto et al., 2002) , Newcastle disease virus (Huang et al., 2004) , adenovirus (Wang et al., 2017b) , duck enteritis virus . The AAAV also was a powerful vector for gene delivery (Perozo et al., 2008b; Wang et al., 2008b) . So far, the rAAAV vector is mainly prepared in HEK293 cells using the 3-plasmid method (Bossis and Chiorini, 2003; Estevez and Villegas, 2004) , the titer of rAAAV produced with this method is too low to meet the clinical trial. In our previous work, the rAAAV had been successfully produced using the baculovirus expression system (Wang et al., 2017c) , and the titer of rAAAV was significantly higher than that of rAAAV prepared with the traditional method. In the present study, we tried to prepare rAAAV expressing VP1 gene in insect cells. The data of EM and Western blotting analysis indicated that rAAAV produced in insect cells had the typical features of AAAV. The real-time PCR results showed that the rAAAV titer produced in Sf9 cells, approximately 22, 500 VG per Sf9 cells, had been greatly increased. The rAAAV-VP1 expression of a VP1 protein with the expected molecular weight of 27 kDa was demonstrated by western blotting analysis of rAAAV-VP1-infected DF1. These data agree with our previous results on the ability of the rAAAV vector to induce adequate protein expression in vitro (Wang et al., 2008b) . VP1 protein is the major structural protein of picornaviruses and can stimulate neutralizing antibodies in ducklings (Fu et al., 2012; Wang et al., 2014) . To evaluate the immunogenicity of VP1 protein mediated by rAAAV, 1 d ducklings were vaccinated 1 time with rAAAV at a dose of 10 9 VG in a volume of 0.5 mL. The results of our previous work showed that immunization with rAAAV-VP1 at a dose of 10 9 VG was enough to stimulate strong immune responses in ducklings (data not shown), which were in accordance with the previous reports (Perozo et al., 2008a; Perozo et al., 2008b) . The antibodies were detected by the VP1-specific ELISA test as early as week 1 postimmunization in all vaccinated ducklings, reached the climax at week 2, and slowly declined in the following 2 wk. Statistically significant differences were observed between the vaccinated groups and the control groups. Virus neutralization test showed that innoculation with rAAAV-VP1 could induce adequate neutralizing antibodies in ducklings. All these indicated that the expression of VP1 protein mediated by rAAAV in ducklings could induce strong humoral immune response. Viral challenge test was further used to assess whether the humoral immune response induced by rAAAV-VP1 could provide adequate protection in ducklings. Ducklings in negative group showed typical clinical signs including lateral recumbency, opisthotonos within 48-72 h, whereas those innoculated with rAAAV-VP1 or attenuated vaccine showed no apparent signs. According to our previous experiments, when the ducklings showed the clinical sings, they would die within 24 h. In order to investigate the level of viral replication in the target organ, ducklings were euthanized and the livers were collected for the use of quantitative real-time RT-PCR using 3D gene as primers. The data showed that the level of virus copies in both rAAAV-VP1 group and attenuated vaccine group were significantly lower than that of the PBS group, indicating that vaccination with rAAAV-VP1 could decrease DHAV replication in vivo. Overall, the serological and challenge results proved that the immunization of rAAAV-VP1 1 time in 1 d ducklings could not only induce high level of antibody, but also obviously inhibit the replication of DHAV.
In summary, the rAAAV particles expressing the VP1 protein characterized with high titer was successfully produced in insect cells for the first time, and the rAAAV-VP1 could induce strong humoral immune response and significantly inhibit viral replication. Hence, we conclude that rAAAV-based gene delivery system represent a new vaccine candidate for DHAV-I.
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